Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Avelumab in Combination with Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
KCT0003308Phase 2Recruiting
- Sponsor
- Gachon University Gil Medical Center
- Start
- Oct 2018
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, gemcitabine in leiomyosarcoma (LMS), sponsored by Gachon University Gil Medical Center. Started Oct 2018; status: recruiting.
02
Drugs
avelumabgemcitabine
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on KCT0003308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003308.